Task: Question Answering
Input (English): Background Paragraph: Currently, millions of individuals with high cholesterol take a similar type of drug, known as a statin. The drug, an inhibitor of HMG-CoA reductase (3-hydroxy-3-methyl-glutaryl-CoA reductase), the rate limiting enzyme in cholesterol biosynthesis, decreases blood levels of cholesterol by induce the expression of low density lipoprotein (LDL) receptors in the liver. The increased levels of the LDL-receptors stimulate the catabolism of plasma LDL, removing cholesterol from plasma, which is an important determinant of atherosclerosis. You may know of people who take a statin to help with their cholesterol levels. However, these drugs probably work slightly differently in many of those people. In some, it lowers their cholesterol significantly; in others it may lower it only moderately; and in some, it may have no significant effect at all. (Luckily for those individuals, there are multiple versions of the statins, so different drugs can be tested to find the proper combination for that individual.) Why the difference? Because of the genetic background of all people; the different single nucleotide polymorphisms that make us all different. Pharmacogenomics, a combination of pharmacology and genomics (the study of the genome) that refers to the study of the relationship between pharmaceuticals and genetics, may explain and simplify this problem. 
Story: Two university students studied different types of drugs for their exams. Kate studied statins, while Carol studied anti-depressants. 
Question: Which student learned less about rate limiting enzyme in cholesterol biosynthesis?
Output (English): Carol.